Cytokinetics
CYTK
$59.36
Share price
2.54%
Change (1 day)
52.40%
Change (1 year)
Categories
Cytokinetics (CYTK) - P/B ratio
P/B ratio as of May 2024 : -16.1
According to Cytokinetics
's latest financial reports the company has a price-to-book ratio of -16.1.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Cytokinetics - P/B ratio (from 2004 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | -21.2 | -47.27% |
| 2022-12-31 | -40.2 | -354.76% |
| 2021-12-31 | 15.8 | 21.6% |
| 2020-12-31 | 13.0 | -122.6% |
| 2019-12-31 | -57.4 | -530.48% |
| 2018-12-31 | 13.3 | 233.52% |
| 2017-12-31 | 4.00 | -23.55% |
| 2016-12-31 | 5.23 | -13.36% |
| 2015-12-31 | 6.04 | 79.46% |
| 2014-12-31 | 3.36 | -8.18% |
| 2013-12-31 | 3.66 | 173.06% |
| 2012-12-31 | 1.34 | -6.85% |
| 2011-12-31 | 1.44 | -27.37% |
| 2010-12-31 | 1.98 | 12.8% |
| 2009-12-31 | 1.76 | -38.53% |
| 2008-12-31 | 2.86 | 22.58% |
| 2007-12-31 | 2.33 | -23.39% |
| 2006-12-31 | 3.05 | 27.6% |
| 2005-12-31 | 2.39 | -6.71% |
| 2004-12-31 | 2.56 | |
| 2003-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 26.8 | -266.38% | 🇺🇸 USA |
 Trevena TRVN | 2.16 | -113.39% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | 2.19 | -113.57% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | -0.0052 | -99.97% | 🇺🇸 USA |
 Array Technologies ARRY | 3.14 | -119.47% | 🇺🇸 USA |